JP2009544706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544706A5 JP2009544706A5 JP2009521804A JP2009521804A JP2009544706A5 JP 2009544706 A5 JP2009544706 A5 JP 2009544706A5 JP 2009521804 A JP2009521804 A JP 2009521804A JP 2009521804 A JP2009521804 A JP 2009521804A JP 2009544706 A5 JP2009544706 A5 JP 2009544706A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- protective
- active ingredient
- granules
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 72
- 239000008187 granular material Substances 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 9
- 230000000873 masking effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 244000144730 Amygdalus persica Species 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 235000004936 Bromus mango Nutrition 0.000 claims description 3
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 claims description 3
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 claims description 3
- 240000007228 Mangifera indica Species 0.000 claims description 3
- 235000014826 Mangifera indica Nutrition 0.000 claims description 3
- 240000008790 Musa x paradisiaca Species 0.000 claims description 3
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 3
- 235000009184 Spondias indica Nutrition 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 235000010634 bubble gum Nutrition 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical group C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001596 famotidine Drugs 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims description 2
- 229960002428 fentanyl Drugs 0.000 claims description 2
- 229960001165 modafinil Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims 22
- 239000011230 binding agent Substances 0.000 claims 12
- 230000003179 granulation Effects 0.000 claims 7
- 238000005469 granulation Methods 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 4
- 230000004584 weight gain Effects 0.000 claims 3
- 235000019786 weight gain Nutrition 0.000 claims 3
- 239000006172 buffering agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000008122 artificial sweetener Substances 0.000 claims 1
- 235000021311 artificial sweeteners Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000004034 viscosity adjusting agent Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291198A EP1891938A1 (en) | 2006-07-24 | 2006-07-24 | High dose orally dissolvable/disintegrable lyophilized dosage form |
| EP06291458A EP1905429A1 (en) | 2006-09-18 | 2006-09-18 | Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles |
| US11/880,531 US20080031949A1 (en) | 2006-07-24 | 2007-07-23 | High dose orally dissolvable/disintegrable lyophilized dosage form |
| PCT/US2007/016638 WO2008013808A2 (en) | 2006-07-24 | 2007-07-24 | High dose orally dissolvable/disintegrable lyophilized dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544706A JP2009544706A (ja) | 2009-12-17 |
| JP2009544706A5 true JP2009544706A5 (enExample) | 2011-08-04 |
Family
ID=39029455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521804A Pending JP2009544706A (ja) | 2006-07-24 | 2007-07-24 | 高用量の経口的に溶解可能／分解可能な凍結乾燥剤形 |
| JP2009521810A Pending JP2009544707A (ja) | 2006-07-24 | 2007-07-24 | 保護粒子を含有した経口的に溶解可能／分解可能な凍結乾燥剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521810A Pending JP2009544707A (ja) | 2006-07-24 | 2007-07-24 | 保護粒子を含有した経口的に溶解可能／分解可能な凍結乾燥剤形 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080031947A1 (enExample) |
| EP (2) | EP2068824A2 (enExample) |
| JP (2) | JP2009544706A (enExample) |
| CA (2) | CA2658512A1 (enExample) |
| MX (2) | MX2009000861A (enExample) |
| WO (2) | WO2008013833A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080031947A1 (en) * | 2006-07-24 | 2008-02-07 | Cima Labs Inc. | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
| EP2328558A2 (en) * | 2008-08-08 | 2011-06-08 | McNeil-PPC, Inc. | Use of sucralose as a granulating agent |
| EP2359812A1 (en) * | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| EP2525783A1 (en) * | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| EP2645943A1 (en) | 2010-12-02 | 2013-10-09 | Agile Endosurgery, Inc. | Surgical tool |
| US9730885B2 (en) | 2012-07-12 | 2017-08-15 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
| US11058642B2 (en) * | 2013-04-22 | 2021-07-13 | Tower Laboratories Ltd | Tablets with improved friability |
| US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
| WO2018191794A1 (en) | 2017-04-20 | 2018-10-25 | Zeenar Enterprises Pty Ltd | Liquid crystalline dosage form for administering a statin |
| AU2018255718A1 (en) | 2017-04-20 | 2019-12-05 | Zeenar Enterprises Pty Ltd | Fast disintegrating tablet |
| CN111432804A (zh) * | 2017-11-27 | 2020-07-17 | 帝斯曼知识产权资产管理有限公司 | 冻干的多微粒固体剂型 |
| CA3157405A1 (en) | 2019-11-18 | 2021-05-27 | Donald D. EVANS II | Lyophilized cake in straight-walled vial |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH558659A (fr) * | 1969-11-26 | 1975-02-14 | Orsymonde | Procede pour la preparation d'une composition lyophilisee a usage hygienique. |
| GB1447988A (en) * | 1973-04-03 | 1976-09-02 | Orsymonde | Pharmaceutical compositions |
| FR2539626B2 (fr) * | 1983-01-25 | 1985-06-21 | Lafon Labor | Nouveau procede de preparation de formes galeniques utiles notamment en therapeutique, dietetique, cosmetique et diagnostic, et formes obtenues selon ce procede |
| FR2561916B1 (fr) * | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| DE3824399A1 (de) * | 1988-07-19 | 1990-01-25 | Ford Werke Ag | Regelbares ringreibgetriebe |
| FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US5558880A (en) * | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
| US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
| US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| CA2128821A1 (en) * | 1993-07-27 | 1995-01-28 | Dilip J. Gole | Freeze-dried pharmaceutical dosage form and process for separation thereof |
| DK9500167U3 (da) * | 1995-04-27 | 1996-01-12 | Brdr Christensens Haner A S | Afspærringsindretning af "double-block-and-bleed"-typen |
| US5599846A (en) * | 1996-06-28 | 1997-02-04 | Jame Fine Chemicals, Inc. | Phenylephrine tannate compositions |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US5976577A (en) * | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6740341B1 (en) * | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
| AU2023401A (en) * | 1999-12-01 | 2001-06-12 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| US6754511B1 (en) * | 2000-02-04 | 2004-06-22 | Harris Corporation | Linear signal separation using polarization diversity |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2003055197A (ja) * | 2001-06-07 | 2003-02-26 | Tanabe Seiyaku Co Ltd | 機能性粒子含有口腔内速崩壊性製剤 |
| CA2449731A1 (en) * | 2001-06-07 | 2002-12-19 | Tanabe Seiyaku Co., Ltd. | Functional grain-containing preparations quickly disintegrated in the oral cavity |
| US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
| EP1496867A1 (en) * | 2002-04-08 | 2005-01-19 | Lavipharm Laboratories, Inc. | Drug-complex microparticles and methods of making/using same |
| CA2497176A1 (en) * | 2002-09-04 | 2004-03-18 | Ranbaxy Laboratories Limited | Taste masked dosage forms and processes for their preparation |
| US7994214B2 (en) * | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
| US20050123596A1 (en) * | 2003-09-23 | 2005-06-09 | Kohane Daniel S. | pH-triggered microparticles |
| US7294347B2 (en) * | 2004-06-21 | 2007-11-13 | Council Of Scientific And Industrial Research | Coating compositions for bitterness inhibition |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
| US20080031947A1 (en) * | 2006-07-24 | 2008-02-07 | Cima Labs Inc. | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
-
2007
- 2007-07-23 US US11/880,503 patent/US20080031947A1/en not_active Abandoned
- 2007-07-23 US US11/880,531 patent/US20080031949A1/en not_active Abandoned
- 2007-07-24 WO PCT/US2007/016690 patent/WO2008013833A2/en not_active Ceased
- 2007-07-24 WO PCT/US2007/016638 patent/WO2008013808A2/en not_active Ceased
- 2007-07-24 MX MX2009000861A patent/MX2009000861A/es active IP Right Grant
- 2007-07-24 CA CA002658512A patent/CA2658512A1/en not_active Abandoned
- 2007-07-24 EP EP07810726A patent/EP2068824A2/en not_active Withdrawn
- 2007-07-24 MX MX2009000849A patent/MX2009000849A/es active IP Right Grant
- 2007-07-24 EP EP07836223A patent/EP2068826A2/en not_active Withdrawn
- 2007-07-24 JP JP2009521804A patent/JP2009544706A/ja active Pending
- 2007-07-24 CA CA002658109A patent/CA2658109A1/en not_active Abandoned
- 2007-07-24 JP JP2009521810A patent/JP2009544707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6544749B2 (ja) | 過量服用を減らすための組成物および方法 | |
| ES2320438T7 (es) | Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s) | |
| JP6066351B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
| US8840924B2 (en) | Compositions and methods of making rapidly dissolving ionically masked formulations | |
| JP3233638B2 (ja) | 凍結乾燥された薬投与形状物の製造方法 | |
| EP0654484B1 (de) | Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlussverbindungen mit Cyclodextrinen und in Form von Granulaten, Kau- oder Brausetabletten | |
| BRPI0707043A2 (pt) | comprimidos matriciais, comprimidos matriciais à base de oxicodona, comprimidos, processo de fabricação dos comprimidos matriciais e uso | |
| JPH06502194A (ja) | 急速崩壊性多粒子状錠剤 | |
| CN1123142A (zh) | 氟西汀药物制剂 | |
| US20230149318A1 (en) | Combinations of nanoparticle-encapsulated cargo entities and methods for making and using same | |
| JPWO2008149440A1 (ja) | 速溶性及び可撓性を有するフィルム製剤 | |
| JP2009544707A5 (enExample) | ||
| JP2009544706A (ja) | 高用量の経口的に溶解可能／分解可能な凍結乾燥剤形 | |
| JP2008508255A (ja) | モダフィニル経口凍結乾燥物 | |
| CA2253377A1 (fr) | Compositions pharmaceutiques pour la liberation prolongee de principes actifs insolubles | |
| Wadhwa et al. | Taste masking: A novel approach for bitter and obnoxious drugs | |
| Yee et al. | Recent advances in orally disintegrating tablet: properties, formulation and production | |
| RS60203B1 (sr) | Pedijatrijska formulacija | |
| CA2593016C (en) | Taste masking system for non-plasticizing drugs | |
| Patel et al. | A Recent Advantage on Gastroretentive Drug Delivery System: An Overview | |
| EP3558268B1 (en) | Droxidopa compositions and methods | |
| ES2288117A1 (es) | Composicion farmaceutica solida de gabapentina. | |
| WO2011135314A2 (en) | Pharmaceutical powder compositions | |
| AU2017258853B2 (en) | Extended release tablet comprising a weight-loss drug | |
| KR101473998B1 (ko) | 에페리손 함유 필름코팅정제 |